IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-47013-0.html
   My bibliography  Save this article

Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients

Author

Listed:
  • Sara De Biasi

    (University of Modena and Reggio Emilia School of Medicine)

  • Domenico Lo Tartaro

    (University of Modena and Reggio Emilia School of Medicine)

  • Anita Neroni

    (University of Modena and Reggio Emilia School of Medicine)

  • Moritz Rau

    (University of Modena and Reggio Emilia School of Medicine
    Jena University Hospital)

  • Nikolaos Paschalidis

    (Biomedical Research Foundation Academy of Athens)

  • Rebecca Borella

    (University of Modena and Reggio Emilia School of Medicine)

  • Elena Santacroce

    (University of Modena and Reggio Emilia School of Medicine)

  • Annamaria Paolini

    (University of Modena and Reggio Emilia School of Medicine)

  • Lara Gibellini

    (University of Modena and Reggio Emilia School of Medicine)

  • Alin Liviu Ciobanu

    (University of Modena and Reggio Emilia School of Medicine)

  • Michela Cuccorese

    (Azienda Unità Sanitaria Locale AUSL/AOU Policlinico)

  • Tommaso Trenti

    (Azienda Unità Sanitaria Locale AUSL/AOU Policlinico)

  • Ignacio Rubio

    (Jena University Hospital)

  • Francesca Vitetta

    (University of Modena and Reggio Emilia)

  • Martina Cardi

    (University of Modena and Reggio Emilia)

  • Rafael José Argüello

    (Centre d’Immunologie de Marseille-Luminy)

  • Diana Ferraro

    (University of Modena and Reggio Emilia)

  • Andrea Cossarizza

    (University of Modena and Reggio Emilia School of Medicine
    National Institute for Cardiovascular Research)

Abstract

Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.

Suggested Citation

  • Sara De Biasi & Domenico Lo Tartaro & Anita Neroni & Moritz Rau & Nikolaos Paschalidis & Rebecca Borella & Elena Santacroce & Annamaria Paolini & Lara Gibellini & Alin Liviu Ciobanu & Michela Cuccores, 2024. "Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47013-0
    DOI: 10.1038/s41467-024-47013-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-47013-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-47013-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47013-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.